30 completed, 12 unknown, 4 active not recruiting, 1 recruiting. 18 Phase 1, 15 Phase 3, 12 Phase 2, 6 Not applicable, 3 Phase 4.
Follow Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST) - Latent Tuberculosis Infection (LTBI) | Not applicable | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 300 | 2025-05-26 | 2026-06-03 |
| Clinical Trials of Quadrivalent Influenza Vaccine Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose), Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose), Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose) - Influenza, Human | Phase 1 / Phase 2 | Recruiting | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 620 | 2025-05-08 | 2026-05-05 |
| BCG for Therapeutic Use Phase Ⅲ Clinical Trial BCG for Therapeutic Use, BCG for Therapeutic Use ( BI SAI JI ) - BCG | Phase 3 | Active not recruiting | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 439 | 2025-04-08 | 2026-04-27 |
| Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) quadrivalent recombinant norovirus vaccine (Pichia pastoris), quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo - Acute Gastroenteropathy Due to Norovirus | Phase 3 | Active not recruiting | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 6600 | 2024-07-27 | 2025-01-23 |
| BCG for Therapeutic Use Phase I Clinical Trial BCG for therapeutic use - Non-muscular Invasive Bladder Cancer | Phase 1 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 10 | 2023-11-22 | 2025-05-31 |
| Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells) - Coronavirus | Not applicable | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 160 | 2023-09-20 | 2023-09-06 |
| Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Placebo - COVID-19 | Phase 1 | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 100 | 2023-09-01 | 2023-09-25 |
| Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of Tuberculin - Latent Tuberculosis Infection | Phase 3 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 780 | 2023-08-03 | 2026-04-30 |
| Phase II Clinical Clical of the Pure Protein Derivatives of BCG Purified Protein Derivative of BCG（BCG-PPD） - Tuberculosis | Phase 1 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 30 | 2023-07-26 | 2025-05-16 |
| Clinical Trial of Mica Mycobacterium Vaccae for Injection - Latent Tuberculosis Infection | Phase 4 | Active not recruiting | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 6800 | 2023-04-19 | 2024-06-25 |
| Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected - Latent Tuberculosis Infection | Phase 4 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 7500 | 2023-04-17 | 2024-09-19 |
| Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells) - Coronavirus | Not applicable | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 450 | 2023-03-17 | 2024-05-13 |
| Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine Investigational Vaccine(0.25ml/vial), Investigational Vaccine(0.5ml/vial), Active compared Vaccine - Prevention of Influenza | Phase 3 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 2550 | 2023-02-18 | 2024-01-10 |
| A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel Coronavirus Protein Vaccine (CHO cells) - COVID-19 | Phase 3 | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 400 | 2022-11-07 | 2022-11-15 |
| Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell), Inactivated COVID-19 vaccine (Vero Cell) - COVID-19 | Not applicable | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 272 | 2022-08-29 | 2024-07-26 |
| To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2 Recombinant Novel Coronavirus vaccine (CHO Cells) - COVID-19 | Not applicable | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 240 | 2022-04-29 | 2023-06-08 |
| Safety Study of COVID19 Vaccine on the Market Recombinant new coronavirus vaccine (CHO cell) - COVID-19 | Phase 4 | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 100000 | 2022-04-02 | 2023-06-06 |
| A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) - Tuberculosis | Phase 2 | Suspended | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 200 | 2022-02-10 | 2023-11-28 |
| ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization Recombinant novel coronavirus vaccine (CHO cells) - Prevention of COVID-19 | Phase 1 / Phase 2 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 300 | 2022-01-10 | 2023-06-15 |
| ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization Recombinant novel coronavirus vaccine (CHO cells) - Prevention of COVID-19 | Phase 1 / Phase 2 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 300 | 2021-12-29 | 2022-09-29 |
Showing 20 of 48. Sign in to see all of them.
Tuberculosis (14) · COVID-19 (12) · Coronavirus Infections (6) · Latent Tuberculosis (4) · Influenza, Human (1) · Urinary Bladder Neoplasms (1)
Population Groups (8) · Adjuvants, Pharmaceutic (3) · Injections (3) · BCG Vaccine (2) · Therapeutic Uses (2) · Tuberculin (2) · Vaccines (2) · Biological Products (1) · ESAT-6-CFP10 fusion protein (1) · Influenza Vaccines (1)
China (40) · Indonesia (2) · Uzbekistan (2) · Ecuador (1) · Pakistan (1)
Shuihua Lu, Bachelor (5) · Tao Huang (4) · Tao Huang, Bachelor (4) · Qi Wu, Master (3) · Fangjun Li, Bachelor (2) · Huakun Lv (2) · Ting Huang, Master (2) · Wei Lu, Master (2) · Weihua Wang, Doctor (2) · Yi Mo, Master (2) · Debiao Qiao, Director (1) · Erkin Musabaev, Dr. (1) · Fei Jin (1) · Guan Liu, Master (1)
PMID 33773111, PMID 34021314, PMID 36560565, PMID 36803632, PMID 27413070, PMID 35507481, PMID 36856580, PMID 37877219, PMID 38574739, PMID 38641791, PMID 38704251, PMID 40560769